

Direct Synthesis of Quinazolines through Copper-Catalyzed Reaction of Aniline-Derived Benzamidines

Yusuke Ohta, Yusuke Tokimizu, Shinya Oishi, Nobutaka Fujii, and Hiroaki Ohno

Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo-ku, Kyoto 606-8501, Japan

E-mail: hohno@pharm.kyoto-u.ac.jp; nfujii@pharm.kyoto-u.ac.jp

Table of Contents

Experimental Section	S2
Table S1. Selected Results of Reaction Optimization	S9
NMR Spectra	S10

Experimental Section

General Methods. IR spectra were determined on a JASCO FT/IR-4100 spectrometer. Exact mass (HRMS) spectra were recorded on JMS-HX/HX 110A mass spectrometer. ¹H NMR spectra were recorded using a JEOL AL-500 spectrometer at 500 MHz frequency. Chemical shifts are reported in δ (ppm) relative to Me₄Si (in CDCl₃) as internal standard. ¹³C NMR spectra were recorded using a JEOL AL-500 and referenced to the residual CHCl₃ signal. Melting points were measured by a hot stage melting points apparatus (uncorrected). For column chromatography, Wakosil C-300 was employed.

5-Fluoro-2-iodobenzoic acid and **1a** is commercially available.

5-Methyl-2-iodosylbenzoic acid,¹ 5-nitro-2-iodosylbenzoic acid,¹ compounds **1b**,² **1c**,³ **1d**,⁴ **1e**,⁵ **1f**,⁶ **1g**,⁶ **1j**,⁷ **1l**,⁶ **1m**,⁸ **2a**,⁹ **2b**,¹⁰ and **2c-f**¹¹ were prepared according to the literatures. Compounds **1h**, **1i**, **1k**,¹² 5-nitro-2-iodobenzoic acid,¹³ and **2g-i**¹¹ were synthesized based on the reported procedures for synthesis of related compounds.

- (1) Katritzky, A. R.; Duell, B. L.; Durst, H. D.; Knier, B. L. *J. Org. Chem.* **1988**, *53*, 3972–3978.
- (2) Wang, J.; Xu, F.; Cai, T.; Shen, Q. *Org. Lett.* **2008**, *10*, 445–448.
- (3) Zhou, L.; Zhang, Y. *Synth. Commun.* **1998**, *28*, 3249–3262.
- (4) Stradi, R.; Verga, G.; Gioia, B. *Synthesis* **1977**, 688–690.
- (5) Sevcik, J. *Monatsch. Chem.* **1969**, *100*, 1307–1309.
- (6) Xiao, Q.; Wang, W.-H.; Liu, G.; Meng, F.-K.; Chen, J.-H.; Yang, Z.; Shi, Z.-J. *Chem. Eur. J.* **2009**, *15*, 7292–7296.
- (7) Rajappa, S.; Nair, M. D.; Advani, B. G.; Sreenivasan, R.; Desai, J. A. *J. Chem. Soc., Perkin Trans. I* **1979**, 1762–1764.
- (8) Papadopoulos, E. P. *J. Org. Chem.* **1974**, *39*, 2540–2542.
- (9) Jiang, M. X.-W.; Rawat, M.; Wulff, W. D. *J. Am. Chem. Soc.* **2004**, *126*, 5970–5971.
- (10) Brand, J. P.; Charpentier, J.; Waser, J. *Angew. Chem., Int. Ed.* **2009**, *48*, 9346–9349.
- (11) Zhdankin, V. V.; Kuehl, C. J.; Krasutsky, A. P.; Bolz, J. T.; Simonsen, A. J. *J. Org. Chem.* **1996**, *61*, 6547–6551.
- (12) Brasche, G.; Buchwald, S. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 1932–1934.
- (13) Kraszkiewicz, L.; Skulski, L. *ARKIVOC* **2003**, *6*, 120–125.

General Procedure for Synthesis of *N*-Phenylbenzamidine: *N*-(4-*tert*-Butylphenyl)benzamidine (1h**).** The mixture of 4-(*t*-butyl)aniline (1.85 mL, 11.6 mmol), benzonitrile (1.00 g, 9.70 mmol), and AlCl₃ (1.27 g, 9.70 mmol) in a pressure flask was reacted at 120 °C for 45 min, and then taken out of the oil bath. Ice water was added to the vigorously stirred hot mixture. After aqueous saturated NaOH was added to this mixture until the pH reached 14, it was extracted with CHCl₃ (3 times). The extract was dried over MgSO₄ and concentrated under reduced pressure. The

residue was recrystallized from CHCl₃–hexane to give pure **1h** (1.79 g, 71% from benzonitrile): colorless crystals: 174–176 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.33 (s, 9H, CMe₃), 4.85 (br s, 2H, 2 × NH), 6.92 (d, *J* = 8.0 Hz, 2H, Ar), 7.36 (d, *J* = 8.0 Hz, 2H, Ar), 7.41–7.47 (m, 3H, Ar), 7.87 (d, *J* = 6.3 Hz, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 31.5 (3C), 34.2, 121.0 (2C), 126.3 (2C), 126.7 (2C), 128.5 (2C), 130.4, 136.0, 145.6, 147.0, 154.6. *Anal.* Calcd for C₁₇H₂₀BrN₂: C, 80.91; H, 7.99; N, 11.10. Found: C, 81.00; H, 7.93; N, 11.03.

N-(3-Bromophenyl)benzamidine (1i). By a procedure described for the preparation of amidine **1h**, benzonitrile (1 g, 9.70 mmol) was converted into **1i** (1.24 g, 47% from benzonitrile) by the reaction with 3-bromoaniline (1.27 mL, 11.6 mmol): colorless crystals; mp 123–125 °C; ¹H NMR (500 MHz, CDCl₃) δ 4.90 (br s, 2H, 2 × NH), 6.90 (d, *J* = 6.9 Hz, 1H, Ar), 7.15–7.22 (m, 3H, Ar), 7.42–7.50 (m, 3H, Ar), 7.82 (d, *J* = 5.7 Hz, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 120.5, 123.0, 124.7, 126.0, 126.8 (2C), 128.6 (2C), 130.81, 130.83, 135.3, 151.2, 155.2. *Anal.* Calcd for C₁₃H₁₁BrN₂: C, 56.75; H, 4.03; N, 10.18. Found: C, 56.75; H, 4.06; N, 10.10.

N-Phenyl-4-(trifluoromethyl)benzamidine (1k) By a procedure described for the preparation of amidine **1h**, 4-(trifluoromethyl)benzonitrile (1.30 mL, 9.70 mmol) was converted into **1k** [1.24 g, 48% from 4-(trifluoromethyl)benzonitrile] by the reaction with aniline (1.06 mL, 11.6 mmol): colorless crystals; mp 157–159 °C; ¹H NMR (500 MHz, CDCl₃) δ 4.89 (br s, 2H, 2 × NH), 6.98 (d, *J* = 7.4 Hz, 2H, Ar), 7.09 (t, *J* = 7.4 Hz, 1H, Ar), 7.37 (dd, *J* = 7.4, 7.4 Hz, 2H, Ar), 7.70 (d, *J* = 8.0 Hz, 2H, Ar), 7.99 (d, *J* = 8.0 Hz, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 121.3 (2C), 122.8, 123.8 (q, *J* = 272.3 Hz), 125.5 (q, *J* = 3.6 Hz, 2C), 127.2 (2C), 129.6 (2C), 132.4 (q, *J* = 32.4 Hz), 139.2, 149.3, 153.3. *Anal.* Calcd for C₁₄H₁₁F₃N₂: C, 66.63; H, 4.20; N, 10.60. Found: C, 63.38; H, 4.17; N, 10.56.

General Procedure for Synthesis of 5-Methyl-1-[(triisopropylsilyl)ethynyl]-1*H*-1λ³-benzo[*d*][1,2]iodoxol-3-one (2g). To the stirred suspension of 5-methyl-2-iodosylbenzoic acid (1.05 g, 3.79 mmol) in CH₃CN was added dropwise trimethylsilyl triflate (0.75 mL, 4.17 mmol) at room temperature under argon. After (trimethylsilyl)(triisopropylsilyl)acetylene (1.06 mL, 4.17 mmol) was added dropwise to the reaction mixture at room temperature, it was stirred at this temperature for 15 min. Then pyridine (0.34 mL, 4.17 mmol) was added dropwise. After 20 min, the solvent was removed under reduced pressure. The residue was extracted with CH₂Cl₂, washed with 1 N HCl and aqueous saturated NaHCO₃, and dried over MgSO₄. Concentration under reduced pressure gave an yellow solid, which was recrystallized from CH₃CN to give **2g** (1.0 g, 59%) as colorless crystals: mp 189–191 °C; IR (neat) 1619 (CO) cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.09–1.22 (m, 21H, 3 × *i*-Pr), 2.52 (s, 3H, CMe), 7.59 (dd, *J* = 8.6, 2.0 Hz, 1H, Ar), 8.13 (d, *J* = 8.6 Hz, 1H, Ar), 8.24 (d, *J* = 2.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.2 (3C), 18.5 (6C), 20.7, 64.6, 111.8, 113.8, 125.8, 131.2, 133.0, 135.6, 142.5, 166.6. *Anal.* Calcd for C₁₉H₂₇IO₂Si: C, 51.58; H, 6.15. Found: C, 51.34; H, 6.00.

5-Fluoro-1-[(triisopropylsilyl)ethynyl]-1*H*-1*λ*³-benzo[*d*][1,2]iodoxol-3-one (2h). A mixture of 5-fluoro-2-iodobenzoic acid (1.0 g, 3.76 mmol) and NaIO₄ (0.84 g, 3.95 mmol) in 30% (v/v) aqueous AcOH (7 mL) was stirred under reflux for 4 h. The mixture was diluted with cold water (20 mL). The precipitate was collected by filtration, washed with ice water and acetone, and air-dried in the dark to give 5-fluoro-2-iodosylbenzoic acid (1.01 g, 94%), which was used without further purification. To the stirred suspension of 5-fluoro-2-iodosylbenzoic acid (0.5 g, 1.77 mmol) in CH₃CN was added dropwise trimethylsilyl triflate (0.34 mL, 1.95 mmol) at room temperature under argon. After (trimethylsilyl)(triisopropylsilyl)acetylene (0.50 mL, 1.95 mmol) was added dropwise to the reaction mixture at room temperature, it was stirred at room temperature for 15 min. Then pyridine (0.16 mL, 1.95 mmol) was added dropwise. After 20 min, the solvent was removed under reduced pressure. The residue was extracted with CH₂Cl₂, washed with 1 N HCl and aqueous saturated NaHCO₃, and dried over MgSO₄. Concentration under reduced pressure gave an yellow solid, which was recrystallized from CH₃CN to give **2h** (0.59 g, 75%) as colorless crystals: mp 181–183 °C; IR (neat) 1623 (CO) cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.08–1.25 (m, 21H, 3 × *i*-Pr), 7.46–7.50 (m, 1H, Ar), 8.09–8.11 (m, 1H, Ar), 8.24 (dd, *J* = 9.2, 4.0 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.2 (3C), 18.5 (6C), 64.1, 108.0 (d, *J* = 6.0 Hz), 114.8–114.9 (m), 119.3 (d, *J* = 24.0 Hz), 122.2 (d, *J* = 25.2 Hz), 127.8, 134.2–134.3 (m), 165.1 (d, *J* = 7.2 Hz), 165.5 (d, *J* = 253.1 Hz). *Anal.* Calcd for C₁₈H₂₄FIO₂Si: C, 48.43; H, 5.42. Found: C, 48.33; H, 5.34.

5-Nitro-1-[(triisopropylsilyl)ethynyl]-1*H*-1*λ*³-benzo[*d*][1,2]iodoxol-3-one (2i). By a procedure described for the preparation of benziodoxolone derivative **2g**, 5-nitro-2-iodosylbenzoic acid (2.0 g, 6.47 mmol) was converted into **2i** (1.84 g, 60%): colorless crystals; mp 201–203 °C; IR (neat) 1624 (CO) cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 1.20–1.30 (m, 21H, 3 × *i*-Pr), 8.52 (dd, *J* = 9.2, 2.3 Hz, 1H, Ar), 8.63 (d, *J* = 9.2 Hz, 1H, Ar), 9.06 (dd, *J* = 2.3 Hz, 1H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.3 (3C), 18.5 (6C), 63.0, 115.0, 123.0, 126.5, 128.2, 129.2, 134.5, 150.7, 166.7. *Anal.* Calcd for C₁₈H₂₄INO₄Si: C, 45.67; H, 5.11; N, 2.96. Found: C, 45.60; H, 4.93; N, 2.97.

General Procedure for Quinazoline Synthesis through Copper-Catalyzed Domino C–H Alkynylation and Cyclization: Synthesis of 2-Phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4a). A mixture of **1a** (25.0 mg, 0.13 mmol), CuBr (3.7 mg, 0.03 mmol), **2i** (90.4 mg, 0.19 mmol), K₂CO₃ (17.6 mg, 0.13 mmol), and MS4Å (300 mg) in benzene was stirred at 80 °C for 1 h. The reaction mixture was concentrated under reduced pressure and purified by column chromatography over silica gel with hexane–EtOAc (50:1) to give **4a** (29.8 mg, 62 %) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 1.03 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.15–1.26 (m, 3H, 3 × CH), 2.99 (s, 2H, CH₂), 7.42–7.56 (m, 4H, Ar), 7.78–7.84 (m, 1H, Ar), 8.00–8.05 (m, 1H, Ar), 8.12 (d, *J* = 8.0 Hz, 1H, Ar), 8.32–8.64 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.6 (6C), 19.4, 122.8, 125.1, 126.3, 128.4 (2C) 128.5, (2C), 129.4, 130.2, 133.2, 138.5, 150.6, 159.5, 172.8; MS (FAB) *m/z* (%): 377 (MH⁺, 100), 333 (60); HRMS (FAB) calcd for C₂₄H₃₃N₂Si (MH⁺): 377.2413; found: 377.2422.

6-Fluoro-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4e). By a procedure described for the preparation of **4a**, **1b** (27.3 mg, 0.13 mmol) was converted into **4e** (26.0 mg, 52%) as a pale yellow solid: mp 72–74 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 6.9 Hz, 18H, 6 × CMe), 1.17–1.25 (m, 3H, 3 × CH), 2.91 (s, 2H, CH₂), 7.46–7.53 (m, 3H, Ar), 7.57–7.61 (m, 1H, Ar), 7.71 (dd, *J* = 9.2, 2.9 Hz, 1H, Ar), 8.04 (dd, *J* = 9.2, 5.2 Hz, 1H, Ar), 8.59–8.61 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.6 (6C), 19.5, 108.7 (d, *J* = 22.8 Hz), 123.1 (d, *J* = 8.4 Hz), 123.3 (d, *J* = 25.2 Hz), 128.4 (2C), 128.5 (2C), 130.3, 132.0 (d, *J* = 8.4 Hz), 138.2, 147.7, 159.2 (d, 2.4 Hz), 160.0 (d, *J* = 248.3 Hz), 172.3 (d, *J* = 4.8 Hz); MS (FAB) *m/z* (%): 395 (MH⁺, 100), 351 (80); HRMS (FAB) calcd for C₂₄H₃₂FN₂Si (MH⁺): 395.2319; found: 395.2310.

6-Chloro-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4f). By a procedure described for the preparation of **4a**, **1c** (29.4 mg, 0.13 mmol) was converted into **4f** (24.2 mg, 46%) as a pale yellow solid: mp 74–76 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.16–1.24 (m, 3H, 3 × CH), 2.93 (s, 2H, CH₂), 7.47–7.53 (m, 3H, Ar), 7.75 (dd, *J* = 9.2, 2.3 Hz, 1H, Ar), 7.96 (d, *J* = 9.2 Hz, 1H, Ar), 8.08 (d, *J* = 2.3 Hz, 1H, Ar), 8.59–8.61 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.5 (6C), 19.6, 123.3, 124.2, 128.5 (4C), 130.5, 131.1, 131.7, 134.0, 138.1, 149.1, 159.8, 172.2; MS (FAB) *m/z* (%): 411 (MH⁺, 100), 367 (80); HRMS (FAB) calcd for C₂₄H₃₂ClN₂Si (MH⁺): 411.2023; found: 411.2024.

6-Bromo-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4g). By a procedure described for the preparation of **4a**, **1d** (35.1 mg, 0.13 mmol) was converted into **4g** (28.4 mg, 49%) as a pale yellow solid: mp 76–78 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.16–1.25 (m, 3H, 3 × CH), 2.93 (s, 2H, CH₂), 7.47–7.53 (m, 3H, Ar), 7.86–7.90 (m, 2H, Ar), 8.25 (d, *J* = 2.3 Hz, 1H, Ar), 8.59–8.61 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.5 (6C), 19.7, 119.6, 123.8, 127.6, 128.5 (4C), 130.5, 131.2, 136.6, 138.1, 149.3, 159.8, 172.1; MS (FAB) *m/z* (%): 457 (MH⁺, ⁸¹Br, 100), 455 (MH⁺, ⁷⁹Br, 100), 413 (80), 411 (80); HRMS (FAB) calcd for C₂₄H₃₂BrN₂Si (MH⁺, ⁷⁹Br): 455.1513; found: 455.1516.

6-Iodo-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4h). By a procedure described for the preparation of **4a**, **1e** (40.9 mg, 0.13 mmol) was converted into **4h** (36.6 mg, 57%) as a pale yellow solid: mp 97–99 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.16–1.23 (m, 3H, 3 × CH), 2.93 (s, 2H, CH₂), 7.48–7.53 (m, 3H, Ar), 7.75 (d, *J* = 8.6 Hz, 1H, Ar), 8.03 (dd, *J* = 8.6, 1.7 Hz, 1H, Ar), 8.48 (d, *J* = 1.7 Hz, 1H, Ar), 8.60 (dd, *J* = 7.7, 1.4 Hz, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.6 (3C), 18.5 (6C), 19.8, 90.9, 124.4, 128.5 (4C), 130.5, 131.2, 134.3 (d, *J* = 8.4 Hz), 138.1, 141.8, 149.6, 159.9, 171.8; MS (FAB) *m/z* (%): 503 (MH⁺, 100), 459 (75); HRMS (FAB) calcd for C₂₄H₃₂IN₂Si (MH⁺): 503.1379; found: 503.1374.

6-Methyl-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4i). By a procedure described for the preparation of **4a**, **1f** (26.8 mg, 0.13 mmol) was converted into **4i** (30.0 mg, 60%) as a pale yellow solid: mp 78–79 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 7.4 Hz, 18H, 6 × CMe),

1.16-1.25 (m, 3H, 3 × CH), 2.56 (s, 3H, CMe), 2.95 (s, 2H, CH₂), 7.44-7.52 (m, 3H, Ar), 7.64 (dd, *J* = 8.6, 1.7 Hz, 1H, Ar), 7.86-7.88 (m, 1H, Ar), 7.92 (d, *J* = 8.6 Hz, 1H, Ar), 8.59-8.68 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.6 (3C), 18.6 (6C), 19.3, 21.9, 122.7, 124.1, 128.35 (2C), 128.40 (2C), 129.1, 130.0, 135.3, 136.1, 138.7, 149.1, 158.9, 172.0; MS (FAB) *m/z* (%): 391 (MH⁺, 100), 347 (50); HRMS (FAB) calcd for C₂₅H₃₅N₂Si (MH⁺): 391.2569; found: 391.2575.

6-Methoxy-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4j). By a procedure described for the preparation of **4a**, **1g** (28.8 mg, 0.13 mmol) was converted into **4j** (31.6 mg, 61%) as a pale yellow solid; mp 92–93 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.05 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.17-1.27 (m, 3H, 3 × CH), 2.93 (s, 2H, CH₂), 3.96 (s, 3H, OMe), 7.34 (d, *J* = 2.9 Hz, 1H, Ar), 7.44-7.52 (m, 4H, Ar), 7.95 (d, *J* = 9.2 Hz, 1H, Ar), 8.28-8.60 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.6 (3C), 18.6 (6C), 19.4, 55.6, 103.1, 123.4, 125.5, 128.1 (2C), 128.4 (2C), 129.8, 130.9, 138.7, 146.5, 157.5, 157.9, 170.9; MS (FAB) *m/z* (%): 407 (MH⁺, 100), 363 (60); HRMS (FAB) calcd for C₂₅H₃₅N₂OSi (MH⁺): 407.2519; found: 407.2509.

6-*tert*-Butyl-2-phenyl-4-[(triisopropylsilyl)methyl]quinazoline (4k). By a procedure described for the preparation of **4a**, **1h** (32.1 mg, 0.13 mmol) was converted into **4k** (37 mg, 67%) as a colorless oil; ¹H NMR (500 MHz, CDCl₃) δ 1.04 (d, *J* = 6.9 Hz, 18H, 6 × CMe), 1.16-1.25 (m, 3H, 3 × CH), 1.44 (s, 9H, CMe₃), 3.00 (s, 2H, CH₂), 7.45-7.52 (m, 3H, Ar), 7.91 (dd, *J* = 8.9, 2.0 Hz, 1H, Ar), 7.96 (d, *J* = 8.9 Hz, 1H, Ar), 8.04 (d, *J* = 2.0 Hz, 1H, Ar), 8.59-8.62 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.6 (3C), 18.6 (6C), 19.4, 31.2 (3C), 35.2, 120.2, 122.4, 128.4 (2C), 128.9 (3C), 130.0, 132.0, 138.7, 149.0, 149.1, 159.1, 172.4; MS (FAB) *m/z* (%): 433 (MH⁺, 100); HRMS (FAB) calcd for C₂₈H₄₁N₂Si (MH⁺): 433.3039; found: 433.3031.

Mixture of 5-Bromo- and 7-Bromo-2-phenyl-4-[(triisopropylsilyl)methyl]quinazolines (4l). By a procedure described for the preparation of **4a**, **1i** (35.1 mg, 0.13 mmol) was converted into **4l** (27.7 mg, 48%, 3.7:1 inseparable mixture) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 0.99 (d, *J* = 7.4 Hz, 14.2H, 6 × CMe), 1.03 (d, *J* = 7.4 Hz, 3.8H, 6 × CMe), 1.16-1.25 (m, 3H, 3 × CH), 2.94 (s, 0.4H, CH₂), 3.72 (s, 1.6H, CH₂), 7.47-7.62 (m, 4H, Ar), 7.82 (d, *J* = 7.4 Hz, 0.8H, Ar), 7.96 (d, *J* = 8.6 Hz, 0.2H, Ar), 7.99 (d, *J* = 9.2 Hz, 0.8H, Ar), 8.21 (d, *J* = 1.7 Hz, 0.2H, Ar), 8.58-8.61 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (0.6C), 11.6 (2.4C), 18.5 (1.3C), 18.7 (4.7C), 19.6 (0.2C), 23.1 (0.8C), 119.2 (0.8C), 121.4 (0.2C), 122.7 (0.8C), 126.5 (0.2C), 127.7 (0.2C), 128.5 (2C), 128.6 (2C), 129.8 (0.2C), 130.1 (0.8C), 130.6 (1C), 131.8 (0.2C), 132.6 (0.8C), 133.8 (0.8C), 137.5 (0.8C), 138.1 (0.2C), 151.5 (0.2C), 153.3 (0.8C), 158.4 (0.8C), 160.4 (0.2C), 172.9 (0.8C), 173.1 (0.2C); MS (FAB) *m/z* (%): 457 (MH⁺, ⁸¹Br, 75), 455 (MH⁺, ⁷⁹Br, 75), 413 (100), 411 (100); HRMS (FAB) calcd for C₂₄H₃₂BrN₂Si (MH⁺, ⁷⁹Br): 455.1513; found: 455.1509.

Mixture of 5-Methoxy- and 7-Methoxy-2-phenyl-4-[(triisopropylsilyl)methyl]quinazolines (4m). By a procedure described for the preparation of **4a**, **1j** (28.8 mg, 0.13 mmol) was converted into **4m** (40.1 mg, 77%, 1.25:1 inseparable mixture) as a colorless solid: mp 66–68 °C; ¹H NMR

(500 MHz, CDCl₃) δ 1.00-1.04 (m, 18H, 6 × CMe), 1.16-1.25 (m, 3H, 3 × CH), 2.90 (s, 0.9H, CH₂), 3.46 (s, 1.1H, CH₂), 3.98 (s, 3H, OMe), 6.84 (d, *J* = 7.4 Hz, 0.55H, Ar), 7.14 (dd, *J* = 8.9, 2.6 Hz, 0.45H, Ar), 7.32 (d, *J* = 2.6 Hz, 0.45H, Ar), 7.45-7.52 (m, 3H, Ar), 7.59-7.60 (m, 0.55H, Ar), 7.95-7.68 (m, 0.55H, Ar), 7.99 (d, *J* = 8.9 Hz, 0.45H, Ar), 8.59-8.62 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.47 (1.5C), 11.52 (1.5C), 18.56 (3C), 18.64 (3C), 19.3 (0.5C), 27.7 (0.5C), 55.4 (0.5C), 55.7 (0.5C), 105.6 (0.5C), 107.0 (0.5C), 115.7 (0.5C), 118.1 (0.5C), 119.2 (0.5C), 121.8 (0.5C), 126.6 (0.5C), 128.36 (1C), 128.40 (1C), 128.44 (1C), 128.5 (1C), 130.11 (0.5C) 130.14 (0.5C), 132.9 (0.5C), 138.3 (0.5C), 138.7 (0.5C), 153.1 (0.5C), 153.2 (0.5C), 157.2 (0.5C), 159.1 (0.5C), 160.1 (0.5C), 163.4 (0.5C), 171.6 (0.5C), 172.8 (0.5C); MS (FAB) *m/z* (%): 407 (MH⁺, 100), 363 (60); HRMS (FAB) calcd for C₂₅H₃₅N₂OSi (MH⁺): 407.2519; found: 407.2513.

2-[4-(Trifluoromethyl)phenyl]-4-[(triisopropylsilyl)methyl]quinazoline (4n). By a procedure described for the preparation of **4a**, **1k** (33.7 mg, 0.13 mmol) was converted into **4n** (28.6 mg, 50%) as a colorless solid: mp 64–66 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.03 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.13-1.26 (m, 3H, 3 × CH), 3.00 (s, 2H, CH₂), 7.56-7.60 (m, 1H, Ar), 7.76 (d, *J* = 8.6 Hz, 2H, Ar), 7.83-7.87 (m, 1H, Ar), 8.04 (d, *J* = 8.0 Hz, 1H, Ar), 8.15 (d, *J* = 8.0 Hz, 1H, Ar), 8.74 (d, *J* = 8.6 Hz, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.5 (6C), 19.5, 123.0, 124.1 (q, *J* = 272.3 Hz), 125.2, 125.4 (q, *J* = 3.6 Hz), 126.9, 128.7 (2C), 129.5, 131.7 (q, *J* = 32.4 Hz, 2C), 133.5, 141.9, 150.5, 158.1, 173.3; MS (FAB) *m/z* (%): 445 (MH⁺, 80), 401 (100); HRMS (FAB) calcd for C₂₅H₃₂F₃N₂Si (MH⁺): 445.2287; found: 445.2285.

2-(4-methoxyphenyl)-4-[(triisopropylsilyl)methyl]quinazoline (4o). By a procedure described for the preparation of **4a**, **1l** (28.8 mg, 0.13 mmol) was converted into **4o** (31.4 mg, 61%) as a colorless solid: mp 69–71 °C; ¹H NMR (500 MHz, CDCl₃) δ 1.03 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.15-1.26 (m, 3H, 3 × CH), 2.96 (s, 2H, CH₂), 3.89 (s, 3H, OMe), 7.01-7.04 (m, 2H, Ar), 7.47-7.51 (m, 1H, Ar), 7.77-7.80 (m, 1H, Ar), 7.98 (d, *J* = 8.0 Hz, 1H, Ar), 8.09 (d, *J* = 8.6 Hz, 1H, Ar) 8.56-8.59 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.6 (6C), 19.3, 55.3, 113.8 (2C), 122.6, 125.1, 125.8, 129.2, 130.1 (2C), 131.3, 133.1, 150.7, 159.3, 161.5, 172.6; MS (FAB) *m/z* (%): 407 (MH⁺, 100), 363 (55); HRMS (FAB) calcd for C₂₅H₃₅N₂OSi (MH⁺): 407.2519; found: 407.2531.

2-(Thiophen-2-yl)-4-[(triisopropylsilyl)methyl]quinazoline (4p). By a procedure described for the preparation of **4a**, **1m** (25.8 mg, 0.13 mmol) was converted into **4p** (22.2 mg, 46%) as a colorless oil: ¹H NMR (500 MHz, CDCl₃) δ 1.03 (d, *J* = 7.4 Hz, 18H, 6 × CMe), 1.15-1.26 (m, 3H, 3 × CH), 2.93 (s, 2H, CH₂), 7.17 (dd, *J* = 4.9, 3.7 Hz, 1H, Ar), 7.47-7.51 (m, 2H, Ar), 7.77-7.81 (m, 1H, Ar), 7.95 (d, *J* = 8.6 Hz, 1H, Ar), 8.07-8.09 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 11.5 (3C), 18.6 (6C), 19.1, 122.7, 125.2, 126.0, 128.1, 128.6, 129.0, 129.4, 133.4, 144.8, 150.5, 156.6, 173.1; MS (FAB) *m/z* (%): 383 (MH⁺, 100), 339 (65); HRMS (FAB) calcd for C₂₂H₃₁N₂SSi (MH⁺): 383.1977; found: 383.1979.


4-Methyl-2-phenylquinazoline (5). To a stirred solution of **4a** (79 mg, 0.21 mmol) in THF (0.87 mL) and AcOH (0.044 mL) was added dropwise TBAF (1.0 mol/L in THF; 0.315 mL, 0.315 mmol) at room temperature. After stirring the mixture at this temperature for 4.5 h, the mixture was concentrated under reduced pressure. The residue was purified by column chromatography over alumina with hexane–EtOAc (30:1) to give **5** (35 mg, 76%) as a colorless solid: mp 85–87 °C; ¹H NMR (500 MHz, CDCl₃) δ 3.00 (s, 3H, CMe), 7.47–7.57 (m, 4H, Ar), 7.82–7.85 (m, 1H, Ar), 8.06 (d, *J* = 8.6 Hz, 2H, Ar), 8.61–8.63 (m, 2H, Ar); ¹³C NMR (125 MHz, CDCl₃) δ 22.0, 123.0, 124.9, 126.8, 128.5 (4C), 129.2, 130.3, 133.5, 138.3, 150.4, 160.2, 168.2; MS (FAB) *m/z* (%): 221 (MH⁺, 100); HRMS (FAB) calcd for C₁₅H₁₃N (MH⁺): 221.1087; found: 221.1084.

Table S1. Selected Results of Reaction Optimization


entry	catalyst/reagent (equiv)	base (1 equiv)	additive (equiv)	solvent	R ¹	R ²	results
							4
1	Cu(OTf) ₂ (1.1)	–	–	DMF	TIPS	H	isomerization
2	Cu(OAc) ₂ (1.1)	–	–	DMF	TIPS	H	isomerization
3	CuCl (1.1)	–	–	DMF	TIPS	H	no reaction
4	CuBr (1.1)	–	–	DMF	TIPS	H	no reaction
5	Cu(OTf) ₂ (1.1)	–	–	DMF	C(Me) ₂ OH	H	isomerization
6	Cu(OAc) ₂ (1.1)	–	–	DMF	C(Me) ₂ OH	H	isomerization
7	CuCl (1.1)	–	–	DMF	C(Me) ₂ OH	H	no reaction
8	CuBr (1.1)	–	–	DMF	C(Me) ₂ OH	H	no reaction
9	Cu(OAc) ₂ (1.1)	–	CsF (2)	DMF	Ph	TMS	isomerization
10	Cu(OAc) ₂ (1.1)	–	TBAF (2)	DMF	Ph	TMS	isomerization
11	Cu(OAc) ₂ (1.1)	–	–	DMF	Ph	TMS	isomerization
16	Cu(OAc) ₂ (0.5)	–	AcOH (5)	DMSO	Ph	H	isomerization
17	Cu(OAc) ₂ (0.5)	–	AcOH (5)	DMSO	Ph	TMS	isomerization
18	Cu(OAc) ₂ (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	4a (<16%) ^a
19	Cu(OAc) ₂ (0.2)	K ₂ CO ₃	AgOTf (0.2)	toluene	TIPS	Br	4a (<5%) ^a
19	CuOAc (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	4a (<5%) ^a
20	Cu(OTf) ₂ (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	no reaction
21	CuBr ₂ (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	no reaction
22	CuCl ₂ (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	no reaction
23	CuOTf (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	no reaction
24	CuBr (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	4a (<38%) ^a
25	CuCl (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	4a (<7%) ^a
26	CuI (0.2)	K ₂ CO ₃	–	toluene	TIPS	Br	4a (<19%) ^a
27	CuBr (0.2)	K ₂ CO ₃	AgOTf (0.2)	toluene	TIPS	Br	complex mixture
28	CuBr (0.2)	K ₂ CO ₃	–	dioxane	TIPS	Br	trace
29	CuBr (0.2)	K ₂ CO ₃	–	DMF	TIPS	Br	4a (<5%) ^a
30	CuBr (0.2)	K ₂ CO ₃	–	benzene	TIPS	Br	4a (<47%) ^a
31	CuBr (0.2)	K ₂ CO ₃	–	xylene	TIPS	Br	4a (<34%) ^a
32	CuBr (0.2)	K ₂ CO ₃	–	CH ₂ Cl ₂	TIPS	Br	4a (<24%) ^a
33	CuBr (0.2)	K ₂ CO ₃	–	EtCN	TIPS	Br	4a (<5%) ^a
34	CuBr (0.2)	K ₂ CO ₃	–	DME	TIPS	Br	4a (<6%) ^a
35	CuBr (0.2)	Na ₂ CO ₃	–	benzene	TIPS	Br	4a (<12%) ^a
36	CuBr (0.2)	Cs ₂ CO ₃	–	benzene	TIPS	Br	4a (<22%) ^a
37	CuBr (0.2)	NaHCO ₃	–	benzene	TIPS	Br	4a (<40%) ^a
38	CuBr (0.2)	KOAc	–	benzene	TIPS	Br	trace
39	CuBr (0.2)	CsOAc	–	benzene	TIPS	Br	trace
40	CuBr (0.5)	CsOAc	–	benzene	TIPS	Br	4a (<33%) ^a
41	CuBr (1.0)	CsOAc	–	benzene	TIPS	Br	4a (<34%) ^a
42	CuBr (1.5)	CsOAc	–	benzene	TIPS	Br	4a (<46%) ^a

^a Containing some inseparable impurities.


single_pulse
F:\論文\quinazolineNMRchart\substrate\1h-0-1-1.als



1h-0-1-1.als
single_pulse
1H
10-03-2010 11:48:01
OBNUC 1H
EXMOD single_pulse, ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.35 usec
IRNUC 1H
CTEMP 24.8 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 38




single_pulse
F:\論文\quinazoline\NMR\charter\substrate\1h-0-1-1.als



```



1h-0-1-1.als
single_pulse
1H
single_pulse, ex2
500.16 MHz
2.41 kHz
6.01 Hz
13107
7507.39 Hz
8
1.7459 sec
5.0000 sec
6.35 usec
1H
24.8 c
CDCL3
0.00 ppm
0.12 Hz
38
IRNUC
CTEMP
SLVNT
EXREF
BF
RGAIN

```




single pulse decoupled gated NOE


F:\論文\quinazoline\NMR\NMRchart\substrate\1h-0-1-carbon-1.als



single_pulse
F:\論文\quinazoline\NMR\NMRchart\substrate\1i-N-287-1.als




DFILE 1i-N-287-1.als
COMNT single_pulse
DATIM 10-03-2010 09:25:35
OBNUC 1H
EXMOD single_pulse, ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.35 usec
IRNUC 1H
CTEMP 24.3 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 42




single pulse decoupled gated NOE

F:\熳文\quinazoline\NMR\NMRchart\substrate\1i-N-287-carbon-1.als

DFILE 1i-N-287-carbon-1.als
COMNT single pulse decoupled gated NOE
DATIM 10-03-2010 10:13:32
13C OBNUC
EXMOD single_pulse_dec
OBFRQ 125, 77 MHz
OBSET 7, 87 kHz
OBFTN 4, 21 Hz
POINT 26214
FREQU 31446, 06 Hz
SCANS 1000
ACQTM 0. 8336 sec
PD 2. 0000 sec
PW1 3. 50 usec
IRNUC 1H
CTEMP 24. 9 c
SLVNT CDCL₃
EXREF 77. 00 ppm
BF 1, 20 Hz
RGAIN 60




single_pulse
F:\論文\quinazoline\NMR\chart\1k-N-206-1.als



```


DFILE 1k-N-206-1.als
COMNT single pulse
DATIM 16-03-2010 19:45:46
OBNUC 1H
EXMOD single_pulse, ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.35 usec
IRNUC 1H
CTEMP 25.9 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 44

```






single pulse decoupled gated NOE

F:\論文\quinazoline\NMR\chart\substrate\1k-N-206-carbon-1.als



DFILE 1k-N-206-carbon-1.als
COMNT single pulse decoupled gated NOE
DATIM 17-03-2010 10:09:29
13C
EXMOD single_pulse_dec
OBFRQ 125,77 MHz
OBSET 7.87 kHz
OBFIN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 26.4 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 58






```

DFILE 2g-N-252-1.als
COMNT singl e_pul se
DATIM 12-03-2010 13:45:35
OBNUC 1H
EXMOD single_pulse_ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.35 usec
IRNUC 1H
CTEMP 25.7 c
SLVNT CLCL3 0.00 ppm
EXREF BF 0.12 Hz
RGAIN 40


```

single pulse decoupled gated NOE

F:\論文\quinazoline\NMR\chart\substrate\2g-N -252-carbon-1.als





2g-N -252-carbon-1.als
single pulse decoupled gated NOE
DFILE 2g-N -252-carbon-1.als
COMNT single pulse decoupled gated NOE
DTIM 12-03-2010 14:33:32
13C
OBNUC
EXMOD
OBFRQ
OBSET
OBFIN 125,77 MHz
7.87 kHz
4.21 Hz
POINT 26214
FREQU 31446,06 Hz
SCANS 1000
ACQTM 0.83336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 26.2 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 60






single_pulse

F:\論文\quinazoline\NMR\Rechart\substrate\2h-N-246-1.als





single pulse decoupled gated NOE

F:\Y\谱文\quinazoline\NMR\NMRchart\substrate\2h-N-246-carbon-1.als




F:論文QuinazolineNMRNMRchartsubstrateYsubstrateYi-N-257-1. als





single pulse decoupled gated NOE


F:\論文\quinazoline\NMR\NMRchart\substrate\2i-N-257-carbon-1.als


DFILE 2i-N-257-carbon-1.als
COMNT single pulse decoupled gated NOE
DATIM 12-03-2010 17:42:50
13C
EXMOD single_pulse_dec
OBFRQ 125, 77 MHz
OBSET 7, 87 kHz
OBFIN 4, 21 Hz
POINT 26214
FREQU 31446, 06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PWL 3.50 usec
IRNUC 1H
CTEMP 26.5 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 60






















single_pulse


F:\Y\quinazoline\NMRchart\product\4g-0-8-1.als




































single pulse decoupled gated NOE





S39
















single_pulse



F:\論文\quinazoline\NMR\NMRchart\product\4p-0-39-20100310-1.als




single pulse decoupled gated NOE

F:\論文\quinazoline\NMR\chart\product\4p-0-39-20100310-carbon-1.als

4p-0-39-20100310-carbon-1.als
single pulse decoupled gated NOE
DFILE 10-03-2010 15:41:38
COMNT 13C
DTIM 13C
OBNUC single_pulse_dec
EXMOD 125,77 MHz
OBFRQ 125,77 MHz
OBSET 7.87 kHz
OBFTN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 1000
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 25.8 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 60




single_pulse



```


DFILE 5-N-236-1.als
COMNT single_pulse
DTIM 08-12-2009 17:17:17
OBNUC 1H
EXMOD single_pulse, ex2
OBFRQ 500.16 MHz
OBSET 2.41 kHz
OBFIN 6.01 Hz
POINT 13107
FREQU 7507.39 Hz
SCANS 8
ACQTM 1.7459 sec
PD 5.0000 sec
PW1 6.35 usec
IRNUC 1H
CTEMP 25.1 c
SLVNT CDCL3
EXREF 0.00 ppm
BF 0.12 Hz
RGAIN 40

```



single pulse decoupled gated NOE

F:\論文\quinazoline\NMR\NMRchart\product\5-N-236-carbon-1.als



DFILE 5-N-236-carbon-1.als
COMNT single pulse decoupled gated NOE
DATM 08-12-2009 18:00:43
OBNUC ¹³C
EXMOD single_pulse_dec
OBFRQ 125.77 MHz
OBSET 7.87 kHz
OBFTN 4.21 Hz
POINT 26214
FREQU 31446.06 Hz
SCANS 900
ACQTM 0.8336 sec
PD 2.0000 sec
PW1 3.50 usec
IRNUC 1H
CTEMP 26.3 c
SLVNT CDCL₃
EXREF 77.00 ppm
BF 1.20 Hz
RGAIN 60

